https://www.selleckchem.com/Bcl-2.html
Patients who received this combination therapy had a higher grade ≥ 3 adverse event rate more than those who received AI monotherapy (Risk Difference 43%, 95%CI 0.39-0.47). Fulvestrant 500 mg alone significantly improved PFS (risk ratio 0.85, 95%CI 0.72-0.98), but ORR and CBR were similar to those of anastrozole alone. CONCLUSION In the first-line treatment for advanced postmenopausal hormone receptor-positive breast cancer, a combination therapy of CDK4/6 inhibitors and AI showed significant improvement of PFS, ORR, and CBR but with significant i
Respect!
Kommentar
Delen
